US Patent

US10722667 — Nasal administration

Formulation · Assigned to Optinose AS · Expires 2028-12-30 · 3y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a delivery device and method for administering a powdered triptan, such as sumatriptan, to the nasal cavity for treating headaches and neuropathic pain.

USPTO Abstract

A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece.

Drugs covered by this patent

Patent Metadata

Patent number
US10722667
Jurisdiction
US
Classification
Formulation
Expires
2028-12-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Optinose AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.